WuXi Biologics (Cayman) (HKG:2269) reported 3.31 billion yuan in adjusted profit attributable to owners for the first half, compared with 2.39 billion yuan a year ago, a Tuesday bourse filing showed.
Adjusted EPS moved to 0.78 yuan from 0.56 yuan year over year.
For the six months ended June 30, revenue was 11.8 billion yuan, versus 9.95 billion yuan previously, the biotechnology company said.